For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Confidently build antibody panels to interrogate the tumor microenvironment in multiplex using an expanding catalog of immuno-oncology-focused clones. Our recombinant monoclonal antibodies assure supply and consistency between batches for reproducible results and minimal risk to your panel. Whichever multiplex technique or technology you choose, our recombinant monoclonal rabbit antibodies are available in the right formats to maximize your success.
Our dedicated immuno-oncology (IO) team are focused on identifying and prioritizing the most relevant targets in our recombinant monoclonal antibody pipeline. To ensure optimal results for your multiplex imaging experiments, our imaging experts use enhanced immunohistochemical validation procedures, scrutinizing the antibodies in relevant samples and under appropriate conditions.
Figure 1. Multicolor staining images. A) Multicolor IMC™ image on FFPE tonsil. Image was acquired using the Fluidigm Hyperion™ Imaging System (credit to Goodman Cancer Research Centre, McGill University). B) 7 color IHC-IF multiplex image on FFPE tonsil using RabMAb® antibodies to PD1 [CAL20] ab237728 (orange), PD-L1 [CAL10] ab237726 (green), CD68 [SP251] ab192847 (yellow), CD3 [SP7] ab16669 (red), Ki67 [SP6] ab16667 (light blue), and mouse monoclonal PanCK [C-11] ab7753 (grey) and DAPI nuclear counterstain (dark blue). Image acquired with a Vectra® Polaris™ Automated Quantitative Pathology Imaging System.
For services beyond our catalog, partnerships can be tailored to support the selection and development of the right clones and formats for your experiment. We can collaborate with you to minimize resource spent on finding and trialing suitable clones, enabling you to focus on building your panel. Screen, discover, and innovate faster.
Daniela Quail is an Assistant Professor at the Goodman Cancer Research Centre at McGill University in Montreal. Her research focuses on the role of the tumor microenvironment (TME) during cancer progression. Using Imaging Mass Cytometry™, Daniela can use about 40 different antibodies on one tissue to get a highly multiplexed image with spatial information to get a comprehensive view of what is going on both in and around a tumor.
Daniela Quail, PhD
“When we first tried to get this technology off the ground, we needed special formulations and Abcam had recombinant carrier-free antibodies that were ideal because they have a much lower lot-to-lot variability. When we perform IMC™, we want to ensure we can get the exact same quality of antibodies for every experiment, so we don’t have to optimize and validate our antibody batches again and again.
Using recombinant antibodies really make sense for scientists investing so much money in antibody-based technologies like IMC™. If we run out of antibody, we don’t want to have to go back to the drawing board and start everything from scratch, it just wastes time. We’ve tested hundreds of antibodies so far and the Abcam carrier-free recombinant antibodies have been the most reliable for us. These antibodies also consistently have a really high percentage of recovery after metal conjugation.”
We can offer you the the following features to aid your multiplex imaging experiments:
4,000+ IHC-validated standard catalog products
Human and mouse species reactivity
Carrier-free, purified format available for all RabMAb® antibodies
Bulk orders available
Connect with us today at email@example.com to discover how we can help accelerate your tumor microenvironment discoveries.
Imaging Mass Cytometry™, Hyperion™ and IMC™ are trademarks of Fluidigm Canada Inc.
Vectra® and Polaris™ are trademarks of Akoya Biosciences Inc.